Pentixapharm Advances PANDA Study, Hosts Earnings Call
Pentixapharm Poised for PANDA Progress Picture a couple of ducks on a pond, calm on top but paddling like hell beneath the surface. That's Pentixapharm right now, charging ahead with their Phase 3 PANDA study while gearing up to spill the beans in an upcoming webcast. It's a biotech chess game, and these folks might just be positioning to yell 'checkmate' down the line....
Continue Reading